News
IPHYF
2.250
NaN%
--
Innate Pharma Raises €30 Million in Private Share Placement to Fund Oncology Pipeline
TipRanks · 11h ago
Innate Pharma Schedules Investor Call as Oncology Pipeline Advances
TipRanks · 5d ago
Innate Pharma Raises €30 Million in Share Offering to Extend Cash Runway
TipRanks · 5d ago
Innate Pharma launches €22.5m share placement to fund ADC pipeline and extend runway
TipRanks · 6d ago
Leerink upgrades Innate Pharma to Outperform after lacutamab deal
TipRanks · 08/11 10:20
Innate Pharma upgraded to Outperform from Market Perform at Leerink
TipRanks · 08/11 10:15
Innate Pharma price target raised to $7 from $5 at H.C. Wainwright
TipRanks · 08/10 16:30
Innate Pharma, Sobi to enable initiation of the TELLOMAK-3 study
TipRanks · 08/10 09:30
Innate Pharma CMO Sonia Quaratino to depart, Markus Jensen to succeed
TipRanks · 08/10 09:30
Innate Pharma Secures Funding and Advances Lacutamab to Phase 3 With New CMO
TipRanks · 08/10 07:23
Innate Pharma CMO to Spotlight Cancer Pipeline at BTIG Bladder Cancer Panel
TipRanks · 07/23 05:47
Innate Pharma completes enrollment in dose escalation of IPH4502 study
TipRanks · 07/21 09:30
Innate Pharma Reports Voting Outcomes from 2026 Annual General Meeting
TipRanks · 05/22 10:30
Innate Pharma to Court Investors at Jefferies Global Healthcare Conference 2026
TipRanks · 05/19 10:33
H.C. Wainwright Sticks to Their Buy Rating for Innate Pharma (IPHA)
TipRanks · 05/14 10:36
Innate Pharma: Buy Rating Reaffirmed on Pipeline Momentum and De‑Risking Catalysts; $8 Price Target Unchanged
TipRanks · 05/14 10:16
Innate Pharma Posts Q1 2026 Results as Key Oncology Trials Advance and Cash Runway Tightens
TipRanks · 05/13 12:42
Innate Pharma Updates Share Capital and Voting Rights as of April 16, 2026
TipRanks · 05/12 10:30
Innate Pharma Schedules May 13 Webcast on First-Quarter 2026 Business Progress
TipRanks · 05/06 10:58
Innate Pharma Plans Investor Meetings at D. Boral Capital Global Conference in New York
TipRanks · 04/23 10:30
More
Webull provides a variety of real-time IPHYF stock news. You can receive the latest news about Innate Pharma Marseille through multiple platforms. This information may help you make smarter investment decisions.
About IPHYF
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.